News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Miravant's (MRVT) Photrex -- SnET2 -- Presented At American Academy of Ophthalmology


10/19/2005 5:11:55 PM

Miravant Medical Technologies (OTCBB:MRVT), a pharmaceutical development company specializing in PhotoPoint(TM) photodynamic therapy (PDT), announced today additional results from analyses of the Photrex(TM) (rostaporfin, SnET2) phase III clinical trials, presented at the American Academy of Ophthalmology (AAO) meeting, New Orleans. Photrex is a proprietary PDT drug in development for the treatment of wet age-related macular degeneration (AMD), a leading cause of blindness in older adults. Based on data from two randomized, placebo controlled two-year trials, clinical investigators reported on:

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES